Roche Receives EMA CHMP Recommendation For Approval Of Macular Degeneration Treatment Susvimo
Benzinga·07/24/2026 10:22:29
语音播报
- Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD
- Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections1-3
- By continuously delivering medicine into the eye through the Contivue® refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per year1-3
- nAMD is a leading cause of blindness in people over the age of 60 and affects 1.7 million in the European Union (EU)4